<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="non-infectious virus particles [45, 46]. It has been confirmed that" exact="ritonavir" post="is an active peptidomimetic inhibitor against HIV-1 and HIV-2"/>
 <result pre="concentration of the combining drugs, which increases the adverse reaction." exact="Ribavirin" post="Ribavirin is a synthetic nucleoside antiviral drug with broad-spectrum"/>
 <result pre="of the combining drugs, which increases the adverse reaction. Ribavirin" exact="Ribavirin" post="is a synthetic nucleoside antiviral drug with broad-spectrum antiviral"/>
 <result pre="[43, 51â€&quot;53]. It was recommended that the combined use of" exact="ribavirin" post="and Î±-interferon or lopinavir, 500Â mg/time for adults with"/>
 <result pre="for the reason that the incidence of adverse reactions of" exact="ribavirin" post="is high and the individualized differences are obvious [54]."/>
 <result pre="individualized differences are obvious [54]. Studies on the effect of" exact="ribavirin" post="in vitro showed that ribavirin could reduce viral infection"/>
 <result pre="Studies on the effect of ribavirin in vitro showed that" exact="ribavirin" post="could reduce viral infection [55]. However, the effectiveness and"/>
 <result pre="reduce viral infection [55]. However, the effectiveness and safety of" exact="ribavirin" post="for COVID-19 still need further clinical trials to confirm."/>
 <result pre="of the virus at concentration of 300Â Î¼mol/L [32, 54]." exact="Emtricitabine" post="and Denofovir Alafenamide Emtricitabine is a nucleoside reverse transcriptase"/>
 <result pre="concentration of 300Â Î¼mol/L [32, 54]. Emtricitabine and Denofovir Alafenamide" exact="Emtricitabine" post="is a nucleoside reverse transcriptase inhibitor which is used"/>
 <result pre="[77, 80]. It has been reported that the combination of" exact="emtricitabine" post="and denofovir alafenamide in clinical trial for the treatment"/>
 <result pre="treatment of COVID-19 was applied with great therapeutic effects [32]." exact="Chloroquine" post="Phosphate Chloroquine phosphate is mainly used in the treatment"/>
 <result pre="COVID-19 was applied with great therapeutic effects [32]. Chloroquine Phosphate" exact="Chloroquine" post="phosphate is mainly used in the treatment of malaria"/>
 <result pre="broad-spectrum antiviral effect [84]. Recently, it has been found that" exact="chloroquine" post="phosphate could effectively inhibit the infection of coronavirus at"/>
 <result pre="recommended for antiviral treatment of the COVID-19 as well [88]." exact="Hydroxychloroquine" post="Hydroxychloroquine was developed as an antimalarial drug and has"/>
 <result pre="for antiviral treatment of the COVID-19 as well [88]. Hydroxychloroquine" exact="Hydroxychloroquine" post="was developed as an antimalarial drug and has been"/>
 <result pre="arthritis and lupus erythematosus [89â€&quot;91]. Due to its antiviral activity," exact="hydroxychloroquine" post="has also been used as an adjuvant therapy for"/>
 <result pre="adjuvant therapy for AIDS [92â€&quot;94]. It has been confirmed that" exact="hydroxychloroquine" post="also has therapeutic effect against Ebola virus and dengue"/>
 <result pre="reported that some COVID-19 patients benefited from the treatment with" exact="hydroxychloroquine" post="[96â€&quot;99]. Moreover, its effect for virus elimination could be"/>
 <result pre="Moreover, its effect for virus elimination could be reinforced by" exact="azithromycin" post="[97]. Biological Medicine Interferon Î± Interferon (IFN) is a"/>
 <result pre="2019:2020. 55.FeldJJBernsteinDEYounesZVlierbergheHVLarsenLTatschFFerenciPRibavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and" exact="dasabuvir" post="with ribavirinLiver Int20183891571157529377566 56.BlaisingJPolyakSJPÃ©cheurEIArbidol as a broad-spectrum antiviral: an"/>
 <result pre="against MERS-CoV. Nat Commun 2020, 11, (1), 222. 65.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="for the treatment of Plasmodium vivax malariaPLoS One20171211e018737629121061 83.BaruahUKGowthamarajanKRavisankarVKarriVSimhadriPKSinghVOptimisation of" exact="chloroquine" post="phosphate loaded nanostructured lipid carriers using Box-Behnken design and"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. 86.GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727332074550 87.Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia. Zhonghua"/>
 <result pre="Bethesda (MD), 2012. 90.HuCLuLWanJPWenCThe pharmacological mechanisms and therapeutic activities of" exact="hydroxychloroquine" post="in rheumatic and related diseasesCurr Med Chem201724202241224928302011 91.SchrezenmeierEDÃ¶rnerTMechanisms of"/>
 <result pre="rheumatic and related diseasesCurr Med Chem201724202241224928302011 91.SchrezenmeierEDÃ¶rnerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol202016315516632034323 92.PlantoneDKoudriavtsevaTCurrent and"/>
 <result pre="implications for rheumatologyNat Rev Rheumatol202016315516632034323 92.PlantoneDKoudriavtsevaTCurrent and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
 <result pre="rheumatologyNat Rev Rheumatol202016315516632034323 92.PlantoneDKoudriavtsevaTCurrent and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin"/>
 <result pre="94.KhaliliHDastanFDehghan ManshadiSAA case report of hearing loss post use of" exact="hydroxychloroquine" post="in a HIV-infected patientDaru20142212024450358 95.CaoBParnellLADiamondMSMysorekarIUInhibition of autophagy limits vertical"/>
 <result pre="96.Colson P; Rolain JM; Lagier JC; Brouqui P; Raoult D," exact="Chloroquine" post="and hydroxychloroquine as available weapons to fight COVID-19. Int"/>
 <result pre="Rolain JM; Lagier JC; Brouqui P; Raoult D, Chloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19. Int J Antimicrob"/>
 <result pre="E; La Scola B; Rolain JM; Brouqui P; Raoult D," exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
 <result pre="Scola B; Rolain JM; Brouqui P; Raoult D, Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="Shokouhi S; Saffaei A, Aminoquinolines against coronavirus disease 2019 (COVID-19):" exact="chloroquine" post="or hydroxychloroquine. Int J Antimicrob Agents 2020, 105945. 100.SnellLMMcGahaTLBrooksDGType"/>
 <result pre="Varicella-Zoster virus. J Virol 2018, 92, (21). 102.LiHSKuokDITCheungMCNgMMTNgKCHuiKPYPeirisJSMChanMCWNichollsJMEffect of interferon" exact="alpha" post="and cyclosporine treatment separately and in combination on Middle"/>
 <result pre="J Virol 2018, 92, (21). 102.LiHSKuokDITCheungMCNgMMTNgKCHuiKPYPeirisJSMChanMCWNichollsJMEffect of interferon alpha and" exact="cyclosporine" post="treatment separately and in combination on Middle East respiratory"/>
 <result pre="in-vitro and ex-vivo culture modelAntivir Res2018155899629772254 103.SnyderBGoebelSKoideFPtakRKalkeriRSynergistic antiviral activity of" exact="sofosbuvir" post="and type-I interferons (Î± and Î²) against Zika virusJ"/>
</results>
